GLP-1 Weight Loss: How Much You Lose, Which Drug Works Best & Pills vs Injections (2026)

Key takeaways

• Tirzepatide (Zepbound/Mounjaro) produces more weight loss than semaglutide (Wegovy/Ozempic) at maximum doses: 20.2% vs 13.7% in the only head-to-head trial (SURMOUNT-5, NEJM 2025).
• Most GLP-1 weight loss happens in the first 12 to 15 months. The steepest drop is usually months 4 through 8, after titration is complete. After 15 to 18 months, weight tends to plateau at a new set point.
• Weight regain after stopping is the norm, not the exception. The STEP 1 extension showed patients regained about two-thirds of lost weight within a year of stopping semaglutide. This is a physiological response, not a willpower failure.
• GLP-1 weight loss is available without diabetes. Both Wegovy and Zepbound are FDA-approved specifically for chronic weight management in adults with BMI 30+ (or 27+ with a weight-related condition). A diabetes diagnosis is not required.
• For side effects during weight loss, see GLP-1 side effects. For cost, see GLP-1 cost and insurance.

How much weight do you actually lose on GLP-1 medications?

On average, roughly 13 to 21% of body weight over 68 to 72 weeks, depending on which drug and dose. In the landmark STEP 1 trial (1,961 non-diabetic adults), semaglutide 2.4 mg produced a mean weight loss of 14.9% (about 33 lbs or 15.3 kg) at 68 weeks. In SURMOUNT-1 (2,539 adults), tirzepatide at the highest dose (15 mg) produced 20.9% at 72 weeks (the NEJM primary treatment-regimen estimand; Lilly reported 22.5% under the efficacy estimand, which assumes full adherence). Both included lifestyle intervention (counseling on diet and exercise).

But averages hide a wide range. In STEP 1, 86.4% of semaglutide patients lost at least 5% of body weight, 69.1% lost at least 10%, 50.5% lost at least 15%, and about a third lost 20% or more. In SURMOUNT-1, 91% of tirzepatide patients on the 15 mg dose lost at least 5%, and 57% lost at least 20%. Some people respond dramatically; others respond modestly. The best predictor of long-term success is early response: patients who lose at least 5% in the first 12 to 16 weeks of treatment tend to have the strongest outcomes at one year.

These numbers come from clinical trials with structured support. Real-world results can differ. A 2025 retrospective cohort from an academic obesity clinic found that real-world weight loss was somewhat lower than trial results, partly because of inconsistent dose titration and lower persistence rates. But the general finding holds: GLP-1 medications produce weight loss that was previously only achievable through bariatric surgery.

Which GLP-1 is best for weight loss?

Tirzepatide (Zepbound) produces the most weight loss of any FDA-approved medication. In the only head-to-head comparison (SURMOUNT-5, 751 patients, 72 weeks, New England Journal of Medicine 2025), tirzepatide at maximum tolerated dose produced 20.2% body weight loss versus 13.7% for semaglutide at maximum tolerated dose. That is a 47% greater relative weight loss.

The difference between tirzepatide and semaglutide is not just statistical. In SURMOUNT-5, 31.6% of tirzepatide patients lost at least 25% of their body weight, compared to 16.1% on semaglutide. Women responded more strongly to both drugs than men: women on tirzepatide lost 23.8% versus 18.0% on semaglutide; men lost 17.8% versus 11.0%.

But "best" depends on your situation. Semaglutide has longer real-world track record, more cardiovascular outcome data (SELECT trial: 20% reduction in MACE), and is now available as a daily pill. Tirzepatide produces more weight loss but has a shorter history and a higher list price. Both require a prescription and medical supervision. For a full breakdown of what each drug is and how it works, see our guide to what is GLP-1.

How does GLP-1 work for weight loss?

GLP-1 receptor agonists mimic a natural gut hormone (glucagon-like peptide-1) that signals satiety and slows digestion. The medications work through three overlapping mechanisms: they reduce appetite by acting on hunger centers in the brainstem and hypothalamus, they slow gastric emptying so food stays in the stomach longer (increasing fullness), and they improve insulin sensitivity (which stabilizes blood sugar and reduces cravings driven by glucose swings).

Tirzepatide adds a second mechanism: it also activates GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP signaling has independent effects on fat metabolism and energy balance, which likely explains why tirzepatide produces more weight loss than semaglutide alone. The dual-agonist approach hits two hormonal pathways instead of one.

The appetite reduction is the dominant driver of weight loss. Most patients on GLP-1 medications report dramatically reduced hunger, earlier fullness, less food noise (the constant background thinking about food), and reduced cravings for high-calorie foods. This is a physiological effect, not a behavioral choice, which is why weight regain happens when the medication stops: the hormonal signals return to baseline.

What does GLP-1 weight loss look like week by week?

Weight loss on GLP-1 medications follows a predictable arc: slow start during titration (weeks 1 to 16), steepest loss after reaching full dose (months 4 through 8), gradual deceleration (months 8 through 15), and plateau (month 15 to 18 onward). The first few weeks show minimal scale movement because titration doses are sub-therapeutic, designed for tolerability, not efficacy.

The titration phase is the most frustrating period for patients because the scale barely moves, nausea can be significant, and it feels like the medication is not working. It is working, but at sub-therapeutic doses designed to let your GI system adapt. The real weight loss begins once you reach 1.7 to 2.4 mg of semaglutide or 10 to 15 mg of tirzepatide.

The plateau around month 15 to 18 is also not a failure. It represents a new metabolic equilibrium where reduced caloric intake (from appetite suppression) matches reduced energy expenditure (from lower body weight). Research from the SURMOUNT-1 three-year analysis (176 weeks, Jastreboff et al., NEJM 2025) showed that participants who stayed on tirzepatide held a mean 19.7% weight reduction on the 15 mg dose and 18.7% on 10 mg, versus 1.3% on placebo, with no new safety signals.

GLP-1 before and after: what to realistically expect

A 200-lb person starting semaglutide can realistically expect to lose 25 to 30 lbs over 12 to 15 months. On tirzepatide, the same person might lose 35 to 45 lbs. These are trial averages. Some lose more, some less. Factors that predict stronger response: higher starting BMI, female sex, consistent dose titration to target, early appetite reduction, and adding structured exercise.

What trial averages do not capture: the subjective experience. Patients consistently report that the most dramatic change is not the number on the scale but the relationship with food. Food noise quiets down. Portions shrink naturally. Cravings for sugar and processed food diminish. Meals become smaller and more satisfying. This shift typically begins within the first two to four weeks, well before significant weight loss shows on the scale.

What also changes: waist circumference drops significantly (SURMOUNT-5 showed an 18.4 cm reduction with tirzepatide), blood pressure improves, HbA1c drops (even in non-diabetic patients), triglycerides fall, and inflammatory markers decrease. The metabolic improvements often outpace the weight loss itself.

What does not change: skin elasticity struggles to keep up with rapid weight loss, especially at higher starting weights. Muscle mass declines alongside fat unless you actively resistance train and eat adequate protein (a commonly underappreciated consequence). For nutritional strategies to preserve muscle and address deficiencies, see our best GLP-1 supplements guide.

What is the right GLP-1 dosage for weight loss?

Both semaglutide and tirzepatide follow a stepped titration schedule. You start low and increase every four weeks until you reach the target or maximum tolerated dose. The goal is to minimize nausea and GI side effects while gradually increasing the appetite-suppressing effect.

Most weight loss happens at the higher doses (1.7 to 2.4 mg semaglutide, 10 to 15 mg tirzepatide). Not everyone needs to reach the maximum dose. Some patients find their optimal balance of appetite suppression and tolerability at a mid-range dose and stay there. Your prescriber adjusts based on response, side effects, and weight-loss trajectory.

The titration cannot be safely skipped or accelerated. Studies show that faster dose escalation leads to higher rates of nausea, vomiting, and treatment discontinuation. For details on lower-dose approaches, see our GLP-1 microdosing guide.

Do GLP-1 pills work as well as injections for weight loss?

Very close. The oral semaglutide 25 mg tablet (Wegovy pill, FDA-approved December 2025) produced 13.6% body weight loss in the 64-week OASIS 4 trial, or 16.6% among participants who stayed on treatment, compared to 14.9% for the injectable version in STEP 1. The difference is not clinically significant. Oral tirzepatide is under FDA review with positive SURMOUNT-5 data.

The oral tablet uses an absorption enhancer called SNAC that protects the peptide through the stomach and promotes uptake in a brief window. It must be taken daily (not weekly like the injection), on an empty stomach, with minimal water, and no food or other medications for 30 minutes. These constraints matter for adherence, but for people who refuse injections, the pill is a genuine alternative that produces comparable weight loss.

In OASIS 4, roughly one in three participants who stayed on treatment lost 20% or more of their body weight. The side-effect profile was similar to the injection (nausea, GI symptoms during titration). The pill also reached full dose more slowly because oral absorption is less predictable. For people who want to avoid injections entirely, the oral route is now a legitimate FDA-approved option.

Can you get GLP-1 for weight loss without diabetes?

Yes. Both Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved specifically for chronic weight management in adults without diabetes. The approval criteria: BMI 30+ (obesity), or BMI 27+ with at least one weight-related condition such as hypertension, high cholesterol, or obstructive sleep apnea. A diabetes diagnosis is not required.

This is a common point of confusion because two of the most well-known GLP-1 brand names, Ozempic and Mounjaro, are approved only for type 2 diabetes. Wegovy and Zepbound contain the same active ingredients (semaglutide and tirzepatide, respectively) but are specifically indicated for weight management. The weight-management versions use higher doses (Wegovy goes to 2.4 mg, Ozempic caps at 2.0 mg) and have been studied in non-diabetic populations.

Many people without diabetes use Ozempic off-label for weight loss when Wegovy is unavailable or too expensive. This is legal and common, but insurance coverage is less likely for off-label use. See our GLP-1 cost and insurance guide for strategies.

What happens to your weight when you stop GLP-1?

Weight comes back. The STEP 1 extension trial (Wilding et al., 2022, Diabetes, Obesity and Metabolism) tracked 327 participants who stopped semaglutide after 68 weeks. At week 120 (one year after stopping), they had regained an average of 11.6 percentage points of the 17.3% lost, retaining a net weight loss of only 5.6% from baseline. Most cardiometabolic improvements (blood pressure, lipids, inflammatory markers) also reverted toward pre-treatment levels.

This is not a surprise and should not be interpreted as the medication "not working." Obesity is a chronic condition driven by hormonal and neurological signals that GLP-1 medications modulate but do not permanently alter. When you remove the medication, the biological drivers of weight regain return, just as blood pressure rises when antihypertensive medication is stopped.

The practical implication: most patients who respond well to GLP-1 will need continued treatment to maintain weight loss. The SURMOUNT-1 three-year data is more encouraging: participants who stayed on tirzepatide maintained a mean 19.7% weight reduction at 176 weeks on the 15 mg dose, versus 1.3% on placebo. Sustained treatment produces sustained results.

Does exercise matter when you are on GLP-1?

Yes, critically. GLP-1 weight loss is not pure fat loss. Without resistance training, you lose both fat and muscle. The STEP 1 body composition data (DXA substudy) showed that roughly 40% of weight lost was lean mass. Resistance training shifts that ratio in favor of fat loss and helps preserve metabolic rate, functional strength, and long-term weight maintenance.

The combination of GLP-1 medication plus structured exercise produces better outcomes than medication alone, both in total weight loss and in body composition. The American College of Sports Medicine recommends at least 150 minutes of moderate aerobic activity plus two or more sessions of resistance training per week. For GLP-1 patients specifically, the resistance training component is arguably more important than the cardio, because the medication already handles the caloric deficit through appetite reduction. One input that quietly works against the deficit is alcohol, which adds calories without triggering satiety.

Protein intake matters too. When eating less overall, you need a higher proportion of calories from protein to preserve muscle. Most obesity medicine specialists recommend 1.0 to 1.2 grams of protein per kilogram of body weight per day for GLP-1 patients. For nutritional strategies, see our best GLP-1 supplements guide.

Does Medicare cover GLP-1 for weight loss?

It is evolving. Historically, Medicare Part D excluded coverage for weight-loss drugs. In 2024, the Treat and Reduce Obesity Act gained significant bipartisan support in Congress, which would mandate Medicare coverage of FDA-approved anti-obesity medications. As of mid-2026, some Medicare Advantage plans have begun covering GLP-1 medications for qualifying patients, and Medicare Part D pilot programs are expanding. Coverage varies by plan, region, and specific indication.

If you have Medicare and want GLP-1 for weight loss, start by checking with your plan's formulary. If coverage is denied, manufacturer patient assistance programs (Novo Nordisk and Eli Lilly both have them) and savings card programs may bring the cost down substantially. Patients with a diabetes diagnosis may find coverage easier because GLP-1 drugs are well-established diabetes treatments. For a complete breakdown of coverage strategies, see our GLP-1 cost and insurance guide.

Online GLP-1 weight loss programs: what to look for

Legitimate online GLP-1 programs connect you with a licensed prescriber who evaluates your medical history, prescribes FDA-approved medication if appropriate, and provides ongoing monitoring. Red flags include: no medical evaluation before prescribing, compounded drugs marketed as "same as Ozempic," guaranteed weight-loss promises, and no mention of side effects or contraindications.

The FDA has cracked down hard on online GLP-1 marketing in 2025-2026, issuing over 80 warning letters to telehealth companies making false or misleading claims about compounded GLP-1 products. Look for programs that prescribe FDA-approved brand-name medications (Wegovy, Zepbound, Ozempic, Mounjaro), involve a licensed healthcare provider, include follow-up consultations, and do not make specific weight-loss guarantees. The best programs combine medication with behavioral support (dietary counseling, exercise guidance) because the data consistently shows that medication plus lifestyle intervention outperforms medication alone.

How much do GLP-1 weight loss drugs cost?

List prices range from $1,000 to $1,350 per month. With insurance, co-pays can be $0 to $300 depending on plan and formulary tier. Manufacturer savings cards (NovoCare for Wegovy, Lilly's Zepbound savings program) can bring out-of-pocket costs down to $0 to $25 per month for commercially insured patients who qualify. Without insurance, cash-pay prices at some pharmacies and through manufacturer direct programs are lower than list price.

For a full breakdown of cost-reduction strategies, insurance appeals, and patient assistance programs, see our GLP-1 cost and insurance guide.

Who qualifies for GLP-1 weight loss medications?

FDA-approved criteria for Wegovy and Zepbound: BMI 30+ (obesity), or BMI 27+ with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). You do not need to have tried and failed diet or exercise first, though some insurance plans may require prior authorization documentation.

Who should not take GLP-1 for weight loss: anyone with a personal or family history of medullary thyroid carcinoma (MTC), anyone with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), anyone with a history of pancreatitis, pregnant or breastfeeding women, and anyone with severe gastrointestinal disease. The thyroid warning comes from rodent studies showing thyroid C-cell tumors; this has not been confirmed in humans but remains a labeled contraindication. For the full side-effect profile, see our GLP-1 side effects guide.

Semaglutide vs tirzepatide for weight loss: the head-to-head data

SURMOUNT-5 is the only randomized trial directly comparing the two leading GLP-1 weight loss drugs. Published in the New England Journal of Medicine in 2025, it randomized 751 adults (mean age 45, 64.7% women, no diabetes) to maximum tolerated tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) for 72 weeks. Tirzepatide won on every endpoint.

The primary result: 20.2% mean weight loss with tirzepatide versus 13.7% with semaglutide. That translates to an average of 50 lbs lost on tirzepatide versus 33 lbs on semaglutide. Tirzepatide also won on all five key secondary endpoints: greater proportions achieving 5%, 10%, 15%, 20%, and 25% weight loss thresholds. Notably, 31.6% of tirzepatide patients lost at least 25% of their body weight (roughly a quarter of their starting weight) compared to 16.1% on semaglutide.

An interesting finding: women lost more than men on both drugs. Women on tirzepatide lost 23.8% of body weight versus 18.0% on semaglutide. Men lost 17.8% on tirzepatide versus 11.0% on semaglutide. Researchers speculate this may relate to hormonal differences in how GIP signaling affects fat metabolism, but the mechanism is not yet understood. As lead author Louis Aronne (Weill Cornell Medicine) noted: "In the old days when you put people on a diet, men would lose much more weight than women. With this new category of super-effective drugs, we see that women lose more weight than men."

Waist circumference told a similar story: tirzepatide reduced it by 18.4 cm versus 13.0 cm for semaglutide. Improvements in blood pressure, lipid levels, and glycemic markers were also greater with tirzepatide. The safety profiles were comparable between the two drugs, with GI side effects (nausea, diarrhea, constipation) being the most common in both groups.

Does this mean everyone should choose tirzepatide over semaglutide? Not necessarily. Semaglutide has years more real-world safety data, cardiovascular outcome trial results (the SELECT trial showed 20% MACE reduction), and is now available as a daily pill. Some patients respond better to one drug than the other. But if maximum weight loss is the primary goal and both are accessible, tirzepatide has the stronger data.

How GLP-1 weight loss compares to bariatric surgery

Bariatric surgery (gastric bypass, sleeve gastrectomy) remains the gold standard for maximum weight loss, producing 25 to 35% body weight reduction at 2 to 5 years. GLP-1 medications now approach that range: tirzepatide produces about 21% in trials, and newer drugs in development may push higher. The gap is narrowing, but surgery still wins on total magnitude and long-term durability.

The tradeoffs are real. Surgery is a one-time procedure with permanent anatomical changes, but carries surgical risks (infection, leak, nutritional deficiency), is irreversible, and requires lifelong vitamin supplementation. GLP-1 medication is non-invasive and reversible, but requires ongoing use (and cost) to maintain results, and produces somewhat less total weight loss.

For many patients, the decision is not either/or. Some start with GLP-1 medication and transition to surgery if the response is insufficient. Others have surgery first and add GLP-1 medication later to address weight regain (a growing use case supported by emerging data). The American Society for Metabolic and Bariatric Surgery recognizes both approaches as valid for patients with BMI 35+ or BMI 30+ with obesity-related conditions.

The role of protein and nutrition during GLP-1 weight loss

When you eat less overall (the primary mechanism of GLP-1 weight loss), you need to be more intentional about what you eat. Protein is the priority. Most obesity medicine specialists recommend 1.0 to 1.2 grams of protein per kilogram of body weight per day to minimize muscle loss during rapid weight reduction. A 200-lb person should aim for roughly 90 to 110 grams of protein daily.

Beyond protein, nutrient deficiencies are a real concern. A 2026 review (Urbina et al., Clinical Obesity) of 480,825 GLP-1 patients found increased risk of deficiencies in vitamin B12, iron, zinc, and vitamin D, primarily because patients eat significantly less food overall. These deficiencies can manifest as fatigue, hair loss, brain fog, and weakened immunity. Proactive supplementation is worth discussing with your healthcare provider.

For a complete breakdown of which nutrients GLP-1 patients most commonly lack and evidence-based supplementation strategies, see our best GLP-1 supplements guide. For hair-loss concerns specifically, see GLP-1 and hair loss.

Six-week GLP-1 before and after: setting realistic expectations

At six weeks, most patients are still in the titration phase (usually at 0.5 mg semaglutide or 5 mg tirzepatide). Typical weight loss at this point: 2 to 5 lbs. The scale may barely move. This is normal and expected. The medication is building up in your system and your GI tract is adapting.

What you should notice at six weeks, even without dramatic scale change: reduced appetite, earlier fullness at meals, less food noise (diminished mental preoccupation with food), and possibly some nausea around dose-increase days. These subjective changes are the early indicators that the medication is working physiologically. The weight loss follows.

Patients who expect dramatic six-week transformations (the kind promoted by social media influencers) set themselves up for disappointment and premature discontinuation. The clinical data is clear: the meaningful weight loss window is months 4 through 15. The first four months are preparation, not performance. If after reaching the target dose for at least 8 weeks you have not lost at least 5% of your starting weight, talk to your prescriber about dose adjustment or switching medications.

Why GLP-1 weight loss plateaus and what to do about it

Weight-loss plateaus on GLP-1 medication typically happen between months 12 and 18. The plateau is not the medication "stopping work." It is your body reaching a new energy equilibrium: the reduced caloric intake from appetite suppression now matches the reduced energy expenditure from a lighter body. Your metabolism has adjusted downward, and the drug's appetite-suppressing effect has been offset by a smaller body needing fewer calories.

What to do when you plateau: first, confirm you are still taking the medication consistently and at the prescribed dose. Missed doses reduce average drug levels and can weaken appetite suppression. Second, assess your protein intake and exercise. Inadequate protein accelerates muscle loss, which lowers metabolic rate, which makes plateaus happen sooner. Third, talk to your prescriber. If you are not on the maximum tolerated dose, an increase may reignite weight loss. If you are already at maximum, your prescriber may discuss adding a complementary medication, adjusting meal composition, or reassessing your goals.

One thing not to do: panic and stop the medication. Stopping at a plateau does not maintain the plateau. It triggers regain because the appetite suppression disappears while your metabolism remains adapted to a lower caloric intake. The plateau is actually a success state. It means the medication has brought your weight to a new stable level that your body can sustain as long as treatment continues.

The SURMOUNT-1 three-year data supports this: participants who continued tirzepatide maintained a mean 19.7% weight reduction at 176 weeks on the 15 mg dose, with no new safety signals identified. Patience and persistence, not dose escalation, are usually the right response to a GLP-1 plateau. If you have hit a plateau and want to understand whether your current dose is still appropriate, or whether switching medications might help, your prescriber is the right person to consult. The data supports continued treatment through plateaus.

GLP-1 weight loss and cardiovascular benefit

GLP-1 weight loss is not just cosmetic. The SELECT trial (Lincoff et al., 2023, NEJM) randomized 17,604 adults with obesity and established cardiovascular disease to semaglutide 2.4 mg or placebo. Semaglutide reduced the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% over a median follow-up of 39.8 months. This was the first time an anti-obesity medication demonstrated cardiovascular risk reduction in a dedicated outcomes trial.

The cardiovascular benefits appear to go beyond what weight loss alone would predict. GLP-1 receptor agonists have direct anti-inflammatory effects on blood vessels, reduce C-reactive protein (a marker of systemic inflammation), improve endothelial function, and lower blood pressure independently of weight change. The SELECT results led the American Heart Association and American College of Cardiology to recognize GLP-1 medications for their cardioprotective properties.

This changes the calculus for many patients. GLP-1 medication is not just a weight-loss tool. For people with obesity and cardiovascular risk factors, it is a cardiovascular intervention with weight loss as an important secondary benefit. Insurance payers are increasingly recognizing this distinction, which may improve coverage decisions.

Frequently asked questions

What is glp-1 weight loss?

GLP-1 weight loss refers to using GLP-1 receptor agonist medications (semaglutide, tirzepatide) for chronic weight management. These drugs mimic a natural gut hormone that reduces appetite, slows digestion, and improves insulin sensitivity. In clinical trials, they produce 13 to 22% body weight loss over 12 to 18 months.

How fast do you lose weight on GLP-1?

Most people see minimal weight loss during the first 16 weeks (titration phase). Significant loss begins after reaching the target dose, with the steepest trajectory between months 4 and 8. A typical pattern: 2-4% at 16 weeks, 10-15% at 6 months, 15-21% at 12-15 months, then plateau.

Can you take GLP-1 pills for weight loss?

Yes. Oral semaglutide (Wegovy pill) was FDA-approved in December 2025 for chronic weight management. In the OASIS 4 trial, the daily 25 mg pill produced 13.6% weight loss at 64 weeks (16.6% among those who stayed on treatment), comparable to the weekly injection. Oral tirzepatide is under FDA review.

Is GLP-1 weight loss permanent?

Not without continued treatment. Weight regain after stopping is well-documented. The STEP 1 extension showed patients regained about two-thirds of lost weight within one year of stopping semaglutide. Continued treatment maintains results: the SURMOUNT-1 three-year analysis showed a mean 19.7% weight reduction still in place at 176 weeks on the 15 mg dose.

What is the best GLP-1 for belly fat?

Tirzepatide produced the greatest reduction in waist circumference in head-to-head testing: 18.4 cm reduction versus 13.0 cm for semaglutide (SURMOUNT-5). GLP-1 medications reduce both subcutaneous and visceral abdominal fat, with visceral fat (the metabolically dangerous type around organs) often decreasing disproportionately.

Watch: GLP-1 weight loss explained

Published research cited in this article

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not intended as medical advice. GLP-1 receptor agonists are prescription medications. Consult your healthcare provider about whether GLP-1 treatment is appropriate for you.

GLP-1 Weight Loss by Drug

Metric	Value
Tirzepatide (Zepbound)	20.9–22.5%
Semaglutide injection (Wegovy)	14.9–17%
Oral Wegovy pill	13.6%
Orforglipron (pending)	12.4%